Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kythera Biopharmaceuticals has earned $15.8m in payment from Bayer Consumer Care under the terms of a licensing and collaboration development agreement for Kythera's ATX-101.
Subscribe to our email newsletter
The agreement was signed in August 2010 for the development and commercialization of injectable drug candidate, ATX-101, outside the US and Canada.
Kythera also received €14.1m ($17.5m) to fund certain further global development activities of ATX-101 under the terms of the collaboration arrangement.
Bayer’s decision to pursue continued development and regulatory approvals for ATX-101 after receiving positive results from pivotal European Phase III clinical trials triggered the payments.
The proprietary formulation of synthetic sodium deoxycholate is a well-characterized component of human bile that is naturally occurring in the body and promotes the breakdown of dietary fat.
ATX-101 is designed to be a locally-injected drug that causes proximal, preferential destruction of adipocytes, or fat cells, with minimal effect on surrounding tissue.